Precision BioSciences (DTIL) to Release Quarterly Earnings on Wednesday

Precision BioSciences (NASDAQ:DTIL) is expected to be releasing its earnings data before the market opens on Wednesday, March 26th. Analysts expect Precision BioSciences to post earnings of ($2.09) per share and revenue of $4.28 million for the quarter.

Precision BioSciences Trading Down 1.4 %

Shares of NASDAQ:DTIL opened at $4.98 on Wednesday. The business’s 50-day moving average is $5.12 and its 200 day moving average is $6.79. Precision BioSciences has a 1 year low of $3.61 and a 1 year high of $15.97. The firm has a market capitalization of $38.20 million, a P/E ratio of 83.01 and a beta of 1.59. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22.

Insider Buying and Selling at Precision BioSciences

In other Precision BioSciences news, insider J. Jefferson Smith sold 10,287 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $4.79, for a total transaction of $49,274.73. Following the sale, the insider now owns 87,440 shares in the company, valued at approximately $418,837.60. The trade was a 10.53 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael Amoroso sold 36,838 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $4.67, for a total value of $172,033.46. Following the sale, the chief executive officer now owns 107,087 shares in the company, valued at approximately $500,096.29. The trade was a 25.60 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 8,734 shares of company stock worth $39,946 and have sold 47,279 shares worth $222,064. Company insiders own 4.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on DTIL. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Precision BioSciences in a research report on Wednesday, February 19th. BMO Capital Markets raised Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 target price on the stock in a research report on Friday, January 10th.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.